These benefits, along with a preceding report showing that a little-molecule ACKR3 agonist CCX771 displays anxiolytic-like conduct in mice,2 guidance the thought of targeting ACKR3 as a novel approach to modulate the opioid procedure, which could open new therapeutic avenues for opioid-linked Is